Cargando…

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures

OBJECTIVE: Existing methods for grading lupus flares or improvement require definition-based thresholds as increments of change. Visual analogue scales (VAS) allow rapid, continuous scaling of disease severity. We analysed the performance of the SELENA SLEDAI Physician’s Global Assessment (SSPGA) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thanou, Aikaterini, James, Judith A, Arriens, Cristina, Aberle, Teresa, Chakravarty, Eliza, Rawdon, Joseph, Stavrakis, Stavros, Merrill, Joan T, Askanase, Anca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937422/ https://www.ncbi.nlm.nih.gov/pubmed/31921432 http://dx.doi.org/10.1136/lupus-2019-000365

Ejemplares similares

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments
por: Askanase, Anca, et al.
Publicado: (2015)

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
por: Williams-Hall, Rebecca, et al.
Publicado: (2022)

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
por: Arriens, Cristina, et al.
Publicado: (2020)

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort
por: Davidson, Julie E, et al.
Publicado: (2018)

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
por: Györi, Noémi, et al.
Publicado: (2017)

Coping with systemic lupus erythematosus in patients’ words
por: Cornet, Alain, et al.
Publicado: (2022)

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2020)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
por: Eudy, Amanda M, et al.
Publicado: (2022)

Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus
por: Jallouli, M, et al.
Publicado: (2014)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
por: Meyer, Aurore, et al.
Publicado: (2020)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Strong viral associations with SLE among Filipinos
por: Vista, Evan S, et al.
Publicado: (2017)

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus
por: Carli, L, et al.
Publicado: (2016)

Complement levels and risk of organ involvement in patients with systemic lupus erythematosus
por: Gandino, Ignacio Javier, et al.
Publicado: (2017)

Serum uric acid is associated with damage in patients with systemic lupus erythematosus
por: Elera-Fitzcarrald, Claudia, et al.
Publicado: (2020)

Living with systemic lupus erythematosus in 2020: a European patient survey
por: Cornet, Alain, et al.
Publicado: (2021)

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry
por: Plantinga, Laura C, et al.
Publicado: (2016)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Is frailty a relevant concept in SLE?
por: Katz, Patricia P, et al.
Publicado: (2017)

Associates and predictors of pleurisy or pericarditis in SLE
por: Ryu, Seungwon, et al.
Publicado: (2017)

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors
por: Haque, Sahena, et al.
Publicado: (2018)

Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus
por: Kheir, Joseph M, et al.
Publicado: (2018)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus
por: Zhu, Lisa, et al.
Publicado: (2022)

Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2022)

Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort
por: Al Sawah, Sarah, et al.
Publicado: (2015)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

Predictors of incident proteinuria among patients with SLE
por: Duarte-García, Alí, et al.
Publicado: (2017)

Patient perceptions and preferences of biologic therapies in SLE
por: Lim, S Sam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3j8q44p93j9g16fb8flcm1bj9j